Gene Therapy Market By Vector Type (Viral Vector, Non Viral Vector), By Therapy (In Vivo Therapy, Ex Vivo Therapy), By Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others), By Application (Oncological Dis

Gene Therapy Market By Vector Type (Viral Vector, Non Viral Vector), By Therapy (In Vivo Therapy, Ex Vivo Therapy), By Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others), By Application (Oncological Disorders, Rare Diseases, Neurological Disorders, Other Diseases): Global Opportunity Analysis and Industry Forecast, 2020-2030

Genes are composed of DNA that contains the necessary information to produce proteins that are vital for the human body to function optimally. Few gene mutations are expected to disrupt protein production or not develop these proteins at all, causing genetic disorders. Gene therapy works by repairing, dis-activating (“turning-off”), or replacing dysfunctional genes that cause diseases. It can be used for drug development with the right target and approach. In addition, it can address the root cause of severe disease. For certain disorders, where known genetic mutations lead to deficient or non-functional protein production, gene therapy can “fix” the underlying defect and/or provide a path for the production of functional protein. There are two types of gene therapy based on the location of the target gene on the chromosome includes somatic gene therapy & germ line gene therapy. It can be applied for the treatment of several diseases, such as Parkinson’s, hemophilia, cystic fibrosis, Alzheimer’s, brain tumors, cancer, AIDS, SCID, and others.

An increase in funding for R&D activities pertaining to gene therapy and growth in awareness regarding gene therapy drives the global market growth. In addition, an increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in the prevalence of cancer fuel the growth of the market. However, the high cost associated with the treatment and unwanted immune responses is expected to hamper the market growth in upcoming years.

The gene therapy market is segmented on the basis of vector type, gene type, application, and region. On the basis of vector type, it is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia virus, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. By therapy type, the market is classified into ex vivo therapy and in vivo therapy. By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.

By application, it is divided into oncological disorders, rare diseases, neurological disorders, and other diseases. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.


The key players operating in the global gene therapy market include Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono Genentech, Shanghai Sunway Biotech Co., Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Amgen Inc., Astellas Therapeutics, Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene therapy market analysis from 2020 to 2030 to identify the prevailing gene therapy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gene therapy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gene therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments


By Vector Type

Viral Vector
Non Viral Vector

By Therapy

In Vivo Therapy
Ex Vivo Therapy

By Gene Type

Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Growth factors
Receptors
Others

By Application

Oncological Disorders
Rare Diseases
Neurological Disorders
Other Diseases

By Region

North America
Europe
Asia-Pacific
LAMEA

Key Market Players

Novartis AG
Gilead Sciences.
Jazz Pharmaceuticals
Orchard Therapeutics.
Bristol-Myers Squibb.
Amgen Inc.
Shenzhen SiBiono GeneTech
Shanghai Sunway Biotech Co. Ltd.
Adaptimmune Therapeutics plc
Adverum Biotechnologies Inc.
Abeona Therapeutics Inc.
Applied Genetic Technologies Corporation
Astellas Therapeutics Inc.
Bluebird Bio, Inc.
CRISPR Therapeutics AG
Intellia Therapeutics, Inc.
REGENXBIO Inc.
Sangamo Therapeutics, Inc.
Uniqure N. V., Voyager Therapeutics, Inc.
Merck and Co Inc.
Dendron Corporation